Severe reactivation of hepatitis B virus infection in a patient with hairy cell leukemia: Should lamivudine prophylaxis be recommended to HBsAg-negative, anti-HBc-positive patients?
The reverse seroconversion to hepatitis B virus infection has been sporadically described in onco-haematological patients receiving cytotoxic therapy or allogeneic bone marrow transplantation and can be associated with the development of acute icteric hepatitis. We present a male HBsAg-negative, anti-HBc-positive patient with Hairy Cell Leukemia who developed acute B hepatitis more than 1 year after the last course of 2-CdA and 6 months after splenectomy, while the patient was receiving therapy with alphaIFNr. The acute B hepatitis promptly responded to lamivudine therapy followed by viral clearance.
Orlando
R
R
Dept. of Public Medicine and Social Security, Section of Infectious Diseases, University of Naples Federico II, Via Sergio Pansini 5, 80131, Naples, Italy. raffaele.orlando@unina.it
Tosone
G
G
Tiseo
D
D
Piazza
M
M
Portella
G
G
Ciancia
R
R
Martinelli
V
V
Montante
B
B
Rotoli
B
B
D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000821:virology*; D008297:Male; D014775:Virus Activation / Q000187:drug effects
D000998:Antiviral Agents; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine